XML 69 R25.htm IDEA: XBRL DOCUMENT
v3.22.4

Financial assets and liabilities measured at fair value | 12 Months Ended
--- | ---
Dec. 31, 2022
Fair Value Measurement [Abstract] |
Financial assets and liabilities measured at fair value | Financial assets and liabilities measured at fair value Under IFRS 7 (Financial Instruments: Disclosures), fair value measurements must be classified using a fair value hierarchy with the following levels: •level 1: quoted prices in active markets for identical assets or liabilities (without modification or repackaging); •level 2: quoted prices in active markets for similar assets and liabilities, or valuation techniques in which all important inputs are derived from observable market data; •level 3: valuation techniques in which not all important inputs are derived from observable market data. The valuation techniques used are described in Note B.8.5. The table below shows the balance sheet amounts of assets and liabilities measured at fair value.
|  | 2022 | 2021 | 2020
|  | Level in the fair value hierarchy | Level in the fair value hierarchy | Level in the fair value hierarchy
(€ million) | Note | Level 1 | Level 2 | Level 3 | Level 1 | Level 2 | Level 3 | Level 1 | Level 2 | Level 3
Financial assets measured at fair value |  |  |  |  |  |  |  |  |  |
Quoted equity investments | D.7.1. | 387 |  | — |  | — |  | 396 |  | — |  | — |  | 439 |  | — |  | — |
Unquoted equity investments | D.7.1. | — |  | — |  | 549 |  | — |  | — |  | 427 |  | — |  | — |  | 149 |
Quoted debt securities | D.7.2. | 329 |  | — |  | — |  | 447 |  | — |  | — |  | 426 |  | — |  | — |
Unquoted debt securities not meeting the definition of equity instruments | D.7.3. | — |  | — |  | 115 |  | — |  | — |  | 78 |  | — |  | — |  | 63 |
Contingent consideration relating to divestments | D.7.3. | — |  | — |  | 303 |  | — |  | — |  | 378 |  | — |  | — |  | 483 |
Financial assets held to meet obligations under deferred compensation plans | D.7.3. and D.11. | 512 |  | — |  | — |  | 549 |  | — |  | — |  | 454 |  | — |  | — |
Non-current derivatives | D.7. | — |  | — |  | — |  | — |  | 3 |  | — |  | — |  | 24 |  | — |
Current derivatives | D.11. | — |  | 206 |  | — |  | — |  | 295 |  | — |  | — |  | 58 |  | — |
Mutual fund investments | D.13. | 9,537 |  | — |  | — |  | 5,057 |  | — |  | — |  | 8,703 |  | — |  | — |
Total financial assets measured at fair value |  | 10,765 |  | 206 |  | 967 |  | 6,449 |  | 298 |  | 883 |  | 10,022 |  | 82 |  | 695 |
Financial liabilities measured at fair value |  |  |  |  |  |  |  |  |  |
Bayer contingent purchase consideration arising from the acquisition of Genzyme | D.18. | — |  | — |  | 26 |  | — |  | — |  | 59 |  | — |  | — |  | 104 |
MSD contingent consideration (European vaccines business) | D.18. | — |  | — |  | 204 |  | — |  | — |  | 269 |  | — |  | — |  | 312 |
Shire contingent consideration arising from the acquisition of Translate Bio | D.18. | — |  | — |  | 380 |  | — |  | — |  | 354 |  | — |  | — |  | — |
Contingent consideration arising from acquisition of Amunix | D.18. | — |  | — |  | 165 |  | — |  | — |  | — |  | — |  | — |  | — |
Other contingent consideration arising from business combinations and acquisitions | D.18. | — |  | — |  | 4 |  | — |  | — |  | 32 |  | — |  | — |  | 189 |
Non-current derivatives | D.19. | — |  | 232 |  | — |  | — |  | 6 |  | — |  | — |  | 92 |  | — |
Current derivatives | D.19.5 | — |  | 94 |  | — |  | — |  | 79 |  | — |  | — |  | 205 |  | — |
Total financial liabilities measured at fair value |  | — |  | 326 |  | 779 |  | — |  | 85 |  | 714 |  | — |  | 297 |  | 605 |
No transfers between the different levels of the fair value hierarchy occurred during 2022.

X
- Definition Disclosure of financial assets and liabilities at fair value explanatory. + References No definition available. + Details
Name: | sny_DisclosureOfFinancialAssetsAndLiabilitiesAtFairValueExplanatoryTextBlock
Namespace Prefix: | sny_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair Value Measurement [Abstract] + References No definition available. + Details
Name: | sny_FairValueMeasurementAbstract
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration